Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy

<h2>Background</h2><p dir="ltr">The mechanism of tumor immune escape and progression in colorectal cancer (CRC) is widely investigated in-vitro to help understand and identify agents that might play a crucial role in response to treatment and improve the overall survival...

وصف كامل

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Nassiba Taib (14557385) (author)
مؤلفون آخرون:	Maysaloun Merhi (4246147) (author), Varghese Inchakalody (15263530) (author), Sarra Mestiri (14557379) (author), Shereena Hydrose (14442135) (author), Karama Makni-Maalej (15263533) (author), Afsheen Raza (492657) (author), Fairooz Sahir (6595517) (author), Fouad Azizi (11835843) (author), Parveen B. Nizamuddin (14590613) (author), Queenie Fernandes (14557388) (author), Zeenath Safira K. M. Yoosuf (15263536) (author), Salam Almoghrabi (15263539) (author), Lobna Al-Zaidan (14557394) (author), Alaaeldin Shablak (14778097) (author), Shahab Uddin (154400) (author), Cristina Maccalli (2632465) (author), Mohammed Ussama Al Homsi (15263542) (author), Said Dermime (79420) (author)
منشور في:	2023
الموضوعات:	Biological sciences Biochemistry and cell biology Biomedical and clinical sciences Reproductive medicine Colorectal cancer Decitabine NY-ESO-1 PD-L1 Stemness markers Chemoresistance Immune escape
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

كن أول من يترك تعليقا!

Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy

مواد مشابهة